Free tool
Drug Trial Radar: Oncology
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
2,063
Completed, industry sponsors, Oncology, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting600
- Completed2,063
2,063 trials
Showing 1 to 25, recently updated first.
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT03425643 · 797 participants · Start Apr 24, 2018 · Primary completion Jul 10, 2023
Drug: Pembrolizumab; Placebo and 3 more · For: Non-small Cell Lung Cancer
Sites: Gilbert, Arizona; Goodyear, Arizona; Phoenix, Arizona · 227 sites in all
- Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLCPivotal-lookingCompleted
Shanghai Yizhong Pharmaceutical Co., Ltd.Industry
NCT02667743 · 454 participants · Start May 2015 · Primary completion Jan 2019
Drug: Paclitaxel Micelles for Injection; Paclitaxel Injection and 1 more · For: Non-Small Cell Lung Cancer(NSCLC)
Sites: Guangzhou, China; Shanghai, China; Nanjing, China
- Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate CancerPivotal-lookingCompleted
Curium US LLCIndustry
NCT06235151 · 443 participants · Start Apr 1, 2024 · Primary completion Oct 30, 2026
Drug: Copper Cu 64 PSMA I&T · For: Prostate Cancer; Prostate Adenocarcinoma
Sites: Homewood, Alabama; Little Rock, Arkansas; Fullerton, California · 43 sites in all
- Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT03615326 · 738 participants · Start Oct 5, 2018 · Primary completion Mar 20, 2024
Drug: Pembrolizumab; Placebo and 6 more · For: Gastric Neoplasms; Gastroesophageal Junction Adenocarcinoma
Sites: Los Angeles, California; Monterey, California; Orange, California · 192 sites in all
- Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02504372 · 1,177 participants · Start Nov 6, 2015 · Primary completion Jan 24, 2023
Drug: Pembrolizumab · For: Non-small Cell Lung Cancer
- Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLLPivotal-lookingCompleted
Acerta Pharma BVAstraZeneca (AZN)
NCT02475681 · 535 participants · Start Jun 26, 2015 · Primary completion Feb 8, 2019
Drug: Acalabrutinib; Obinutuzumab and 1 more · For: Chronic Lymphocytic Leukemia
Sites: Goodyear, Arizona; Phoenix, Arizona; Anaheim, California · 155 sites in all
- Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum ChemotherapyPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT03534453 · 225 participants · Start May 29, 2018 · Primary completion Jan 27, 2025
Drug: Olaparib 300mg tablets · For: Relapsed Ovarian Cancer; Following Complete or Partial Response to Platinum Based Chemotherapy; Platinum Sensitive
Sites: Beijing, China; Changsha, China; Chengdu, China · 25 sites in all
- A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETsPivotal-lookingCompleted
Sinotau Pharmaceutical GroupIndustry
NCT05459844 · 196 participants · Start Aug 31, 2022 · Primary completion Jun 26, 2025
Drug: Lutetium[177Lu] Oxodotreotide Injection; Octreotide LAR · For: Neuroendocrine Tumors
Sites: Beijing, China; Fuzhou, China; Xiamen, China · 23 sites in all
- Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)Pivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT03088540 · 712 participants · Start May 29, 2017 · Primary completion Apr 18, 2025
Drug: Pemetrexed; Paclitaxel and 4 more · For: Carcinoma,Non-Small-Cell Lung; Lung Carcinomas, Non-Small-Cell; Non-small-cell Lung Carcinoma and 1 more
Sites: Albury, Australia; Wollongong, Australia; Fitzroy, Australia · 192 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04294810 · 620 participants · Start Mar 4, 2020 · Primary completion Dec 30, 2025
Drug: Atezolizumab; Tiragolumab and 1 more · For: Non-Small Cell Lung Cancer
Sites: Denver, Colorado; New Haven, Connecticut; St. Petersburg, Florida · 132 sites in all
- A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following CystectomyPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04660344 · 761 participants · Start May 3, 2021 · Primary completion Jun 15, 2025
Drug: Atezolizumab · For: Muscle-invasive Bladder Cancer
Sites: Rockledge, Florida; Cleveland, Ohio; Pittsburgh, Pennsylvania · 140 sites in all
- Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04221945 · 1,060 participants · Start May 12, 2020 · Primary completion Jan 7, 2025
Drug: Pembrolizumab; Placebo for pembrolizumab and 1 more · For: Uterine Cervical Neoplasms
Sites: Phoenix, Arizona; Los Angeles, California; Newport Beach, California · 176 sites in all
- A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)Pivotal-lookingCompleted
ALX Oncology Inc.Industry
NCT05002127 · 127 participants · Start Jan 15, 2022 · Primary completion May 24, 2024
Drug: Evorpacept (ALX148); Trastuzumab and 2 more · For: Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Gastric Adenocarcinoma
Sites: Anaheim, California; Los Angeles, California; Nashville, Tennessee · 83 sites in all
- A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT02297438 · 340 participants · Start Mar 23, 2015 · Primary completion Aug 31, 2020
Drug: Palbociclib; Letrozole and 2 more · For: Breast Neoplasms
Sites: Bengbu, China; Hefei, China; Fuzhou, China · 54 sites in all
- 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate CancerPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT04689828 · 469 participants · Start Jun 15, 2021 · Primary completion Oct 2, 2022
Drug: 177Lu-PSMA-617; 68Ga-PSMA-11 and 1 more · For: Prostatic Neoplasms
Sites: Denver, Colorado; Gainesville, Florida; New Orleans, Louisiana · 72 sites in all
- Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha AgentPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04936308 · 453 participants · Start Sep 28, 2021 · Primary completion Oct 28, 2024
Drug: Guselkumab; Placebo · For: Arthritis, Psoriatic
Sites: Mountain Brook, Alabama; Avondale, Arizona; Flagstaff, Arizona · 169 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT03652064 · 395 participants · Start Nov 6, 2018 · Primary completion May 7, 2024
Drug: Daratumumab; Bortezomib and 2 more · For: Multiple Myeloma
Sites: Cerritos, California; Jacksonville, Florida; Fort Wayne, Indiana · 114 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT03036098 · 1,314 participants · Start Mar 24, 2017 · Primary completion Aug 30, 2024
Drug: Nivolumab; Ipilimumab and 3 more · For: Urothelial Cancer
Sites: Anchorage, Alaska; Fresno, California; Santa Rosa, California · 174 sites in all
- Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)Pivotal-lookingCompleted
OctapharmaIndustry
NCT04502030 · 247 participants · Start Oct 5, 2020 · Primary completion Sep 19, 2025
Drug: Panzyga · For: Chronic Lymphocytic Leukemia; Hypogammaglobulinemia
Sites: St. Petersburg, Florida; Columbus, Georgia; Macon, Georgia · 84 sites in all
- Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04210115 · 703 participants · Start Feb 28, 2020 · Primary completion Jan 21, 2026
Drug: pembrolizumab; placebo and 5 more · For: Esophageal Squamous Cell Carcinoma (ESCC); Gastroesophageal Junction Carcinoma (GEJC); Esophageal Adenocarcinoma (EAC)
Sites: Long Beach, California; Columbus, Georgia; Westwood, Kansas · 170 sites in all
- A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia GravisPivotal-lookingCompleted
NCT06149559 · 14 participants · Start Jun 14, 2024 · Primary completion Oct 5, 2026
Drug: rozanolixizumab · For: Generalized Myasthenia Gravis
Sites: Bologna, Italy; Milan, Italy; Naples, Italy · 9 sites in all
- Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL AmyloidosisPivotal-lookingCompleted
Lantheus Germany GmbHIndustry
NCT05184088 · 244 participants · Start Jan 13, 2023 · Primary completion Apr 21, 2026
Drug: [18F]florbetaben · For: Cardiac Amyloidosis; AL Amyloidosis; ATTR Amyloidosis
Sites: Kansas City, Kansas; Philadelphia, Pennsylvania; Pittsburgh, Pennsylvania · 14 sites in all
- Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT05052801 · 547 participants · Start Mar 7, 2022 · Primary completion Jun 20, 2025
Drug: Bemarituzumab; mFOLFOX6 and 1 more · For: Gastric Cancer; Gastroesophageal Junction Adenocarcinoma
Sites: Anchorage, Alaska; Phoenix, Arizona; Cerritos, California · 300 sites in all
- Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal CancerPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT03362177 · 165 participants · Start Sep 30, 2019 · Primary completion Jan 25, 2024
Drug: Romiplostim · For: Chemotherapy-induced Thrombocytopenia
Sites: Jonesboro, Arkansas; Anaheim, California; Orange, California · 117 sites in all
- TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion MutationsPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT04129502 · 354 participants · Start Jan 10, 2020 · Primary completion Sep 22, 2026
Drug: TAK-788; Pemetrexed and 2 more · For: Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Sites: Long Beach, California; Orange, California; Palo Alto, California · 134 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.